Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
$0.39
$0.39
$0.23
$2.83
$26.62M1.55943,490 shsN/A
Axcella Health Inc. stock logo
AXLA
Axcella Health
$0.40
$0.84
$0.34
$41.25
$1.18M0.46267,009 shs6,782 shs
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
$2.91
+4.5%
$3.18
$1.60
$10.48
$111.50M1.35799,878 shs133,655 shs
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$3.28
+2.5%
$3.22
$2.65
$9.55
$177.08M0.85481,444 shs303,242 shs
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$1.97
-0.8%
$3.12
$1.81
$26.96
$10.94M0.54133,306 shs380,089 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.00%0.00%0.00%0.00%0.00%
Axcella Health Inc. stock logo
AXLA
Axcella Health
0.00%0.00%0.00%0.00%0.00%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
0.00%+0.90%-6.86%-25.49%+38.38%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
0.00%+10.81%-0.61%+6.15%-57.57%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
0.00%+7.38%-46.89%-69.48%-88.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.1517 of 5 stars
0.00.00.03.80.60.00.0
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/AN/AN/AN/AN/AN/AN/AN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
1.7285 of 5 stars
3.61.00.00.02.30.00.6
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3.8429 of 5 stars
3.61.00.04.62.00.80.6
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
4.6651 of 5 stars
3.52.00.04.60.63.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.00
N/AN/AN/A
Axcella Health Inc. stock logo
AXLA
Axcella Health
0.00
N/AN/AN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3.14
Buy$20.50605.44% Upside
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3.13
Buy$13.39308.23% Upside
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.00
Buy$72.333,581.09% Upside

Current Analyst Ratings Breakdown

Latest TARA, AXLA, AGTC, XFOR, and VYGR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$21.00
5/2/2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1.50 ➝ $7.00
4/28/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
4/16/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$12.00
4/8/2025
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
$320K83.19N/AN/A$0.26 per share1.51
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/AN/AN/AN/A$1.42 per shareN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/A$4.77 per shareN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$66.96M2.71N/AN/A$5.49 per share0.60
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$31.36M0.36N/AN/A$3.90 per share0.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/A
Axcella Health Inc. stock logo
AXLA
Axcella Health
-$81.19M-$19.25N/AN/AN/AN/A-259.91%N/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$44.60M-$1.72N/AN/AN/AN/A-36.37%-33.29%8/5/2025 (Estimated)
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$65M-$1.46N/AN/AN/A-126.49%-27.36%-21.06%8/5/2025 (Estimated)
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$37.45M$2.140.92N/AN/A46.54%-181.56%-54.36%8/6/2025 (Estimated)

Latest TARA, AXLA, AGTC, XFOR, and VYGR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$0.47-$0.29+$0.18-$0.29N/AN/A
5/6/2025Q1 2025
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 million
5/1/2025Q1 2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$4.13$0.04+$4.17$0.04$7.03 million$28.81 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
N/AN/AN/AN/AN/A
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/AN/AN/AN/AN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/AN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.39
1.40
1.40
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/A
0.80
0.80
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/A
18.03
18.03
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/A
6.10
6.10
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.30
3.70
3.58
CompanyEmployeesShares OutstandingFree FloatOptionable
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
8367.63 million64.86 millionOptionable
Axcella Health Inc. stock logo
AXLA
Axcella Health
112.95 million2.88 millionOptionable
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3038.58 million35.34 millionOptionable
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
10055.34 million51.80 millionOptionable
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
805.79 million5.65 millionOptionable

Recent News About These Companies

X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance
XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha
X4 Pharmaceuticals Analyst Ratings
Earnings Preview For X4 Pharmaceuticals
Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Applied Genetic Technologies stock logo

Applied Genetic Technologies NASDAQ:AGTC

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Axcella Health stock logo

Axcella Health NASDAQ:AXLA

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Protara Therapeutics stock logo

Protara Therapeutics NASDAQ:TARA

$2.91 +0.13 (+4.53%)
Closing price 07/3/2025 03:23 PM Eastern
Extended Trading
$2.88 -0.02 (-0.72%)
As of 07/3/2025 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

Voyager Therapeutics stock logo

Voyager Therapeutics NASDAQ:VYGR

$3.28 +0.08 (+2.50%)
Closing price 07/3/2025 03:33 PM Eastern
Extended Trading
$3.20 -0.07 (-2.29%)
As of 07/3/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

X4 Pharmaceuticals stock logo

X4 Pharmaceuticals NASDAQ:XFOR

$1.96 -0.02 (-0.76%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$1.92 -0.05 (-2.29%)
As of 07/3/2025 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.